ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mantle-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Chicago, IL, USA:

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, s...

Active, not recruiting
Stage IV Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Procedure: biopsy
Biological: alemtuzumab

Phase 2

Northwestern University
Northwestern University

Chicago, Illinois, United States and 1 other location

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...

Enrolling
Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Zanubrutinib

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Evanston, Illinois, United States and 7 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Hinsdale, Illinois, United States of America and 67 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Harvey, Illinois, United States and 130 other locations

Locations recently updated

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib
Drug: Obinutuzumab

Phase 3

AbbVie
AbbVie

Dyer, Indiana, United States and 11 other locations

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...

Enrolling
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib

Phase 1, Phase 2

Juno Therapeutics

Chicago, Illinois, United States and 79 other locations

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Chicago, Illinois, United States and 231 other locations

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia...

Active, not recruiting
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Other: Pharmacological Study
Drug: Romidepsin

Phase 1

National Cancer Institute (NCI)
National Cancer Institute (NCI)

Chicago, Illinois, United States and 11 other locations

ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic...

Enrolling
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Drug: Fludarabine
Biological: ALLO-647

Phase 1, Phase 2

Allogene Therapeutics

Maywood, Illinois, United States and 38 other locations

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Venetoclax

Phase 3

BeiGene
BeiGene

Chicago, Illinois, United States and 178 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems